Vanguard Group Inc. Buys 1,312,192 Shares of Moderna, Inc. $MRNA

Key Points

• Vanguard Group increased its stake in Moderna by 1,312,192 shares (a 3.2% rise) to 41,708,705 shares, representing a 10.72% ownership position valued at about $1.15 billion at quarter-end.
• Institutional ownership is high (75.33%), with several large managers (Geode, Invesco, UBS, Northern Trust, Charles Schwab) also adding to positions, signaling continued institutional accumulation.
• Moderna trades at $23.72 with a $9.27 billion market cap; it reported Q results of ($0.51) EPS beating the -$2.15 estimate and $1.02B revenue (down 45.4% year-over-year), but retains negative margins and an average analyst consensus rating of "Reduce" with a $29.46 price target.

Vanguard Group Inc. grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 3.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 41,708,705 shares of the company's stock after buying an additional 1,312,192 shares during the quarter. Vanguard Group Inc. owned 10.72% of Moderna worth $1,150,743,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRNA. Geode Capital Management LLC raised its position in Moderna by 19.1% during the second quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company's stock valued at $244,458,000 after purchasing an additional 1,420,690 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Moderna by 17.5% in the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock worth $166,801,000 after purchasing an additional 877,162 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Moderna by 0.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,597,236 shares of the company's stock valued at $101,982,000 after purchasing an additional 11,270 shares during the last quarter. Northern Trust Corp increased its position in shares of Moderna by 5.4% during the 1st quarter. Northern Trust Corp now owns 3,119,626 shares of the company's stock valued at $88,441,000 after purchasing an additional 160,572 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Moderna by 12.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock valued at $74,557,000 after buying an additional 285,662 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Stock Up 6.1%

NASDAQ:MRNA opened at $23.72 on Friday. The firm has a market capitalization of $9.27 billion, a P/E ratio of -2.94 and a beta of 2.02. The company has a fifty day moving average of $25.87 and a 200 day moving average of $26.96. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $48.92.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.15) by $1.64. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The company's revenue for the quarter was down 45.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.03 earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on MRNA shares. Morgan Stanley upped their target price on Moderna from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research note on Friday, October 10th. Citigroup cut their price objective on shares of Moderna from $30.00 to $28.00 and set a "neutral" rating for the company in a research note on Thursday, October 23rd. Wolfe Research reaffirmed an "underperform" rating and set a $17.00 target price on shares of Moderna in a report on Thursday. Needham & Company LLC reissued a "hold" rating on shares of Moderna in a research note on Monday, October 20th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $63.00 price objective (down from $69.00) on shares of Moderna in a research note on Friday. Two analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Reduce" and a consensus price target of $29.46.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.